Control of Inflammation and Sustained Improvements in Patient‐Reported Outcomes in Patients With Psoriatic Arthritis: Bimekizumab Two‐Year Results From Two Phase 3 Studies

Laure Gossec, William Tillett, Laura C Coates, Philip J Mease, Maarten de Wit, Dafna D Gladman, Ana‐Maria Orbai, Fabian Proft, Barbara Ink, Rajan Bajracharya, Jérémy Lambert, Patrick Healy, M Elaine Husni · 2026

Read Control of Inflammation and Sustained Improvements in Patient‐Reported Outcomes in Patients With Psoriatic Arthritis: Bimekizumab Two‐Year Results From Two Phase 3 Studies by Laure Gossec, William Tillett, Laura C Coates, Philip J Mease, Maarten de Wit, Dafna D Gladman, Ana‐Maria Orbai, Fabian Proft, Barbara Ink, Rajan Bajracharya, Jérémy Lambert, Patrick Healy, M Elaine Husni (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13184177.txt.

Description

Laure Gossec and colleagues reported two-year results for bimekizumab in two thousand twenty-six. The drug treats psoriatic arthritis, a joint and skin disease. Two large phase three trials supplied the data. One enrolled patients new to biologic drugs. The other enrolled patients whom older drugs had failed. Patient surveys tracked pain, fatigue, and daily function.

Benefits seen early held through two years. Survey gains linked to lower joint inflammation counts. Placebo groups switched to the drug mid-trial. An extension study kept everyone on treatment afterward. Long-term control of inflammation clearly matters to patients. Their daily experience improved alongside clinical measures.

Catalog record

CREATORLaure Gossec, William Tillett, Laura C Coates, Philip J Mease, Maarten de Wit, Dafna D Gladman, Ana‐Maria Orbai, Fabian Proft, Barbara Ink, Rajan Bajracharya, Jérémy Lambert, Patrick Healy, M Elaine Husni
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE52 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13184177

Browse the full library · About the Tower of Babel